PHARMANEST : AN INTERNATIONAL JOURNAL OF ADVANCES IN PHARMACEUTICAL SCIENCES - Volume 4, Issue 6, November - December 2013

Pages: 1625-1638

Print Article   Download XML  Download PDF

FORMULATION AND EVALUATION OF BILAYERED TABLETS OF CANDESARTAN CILEXITIL

Author: M.PRAVEENKUMARREDDY*, CH.S.VIJAYA VANI, P. VISHNU, K B.V YASASWI

Category: Pharmaceutical Sciences

Abstract:

Candesartan cilexitil is an angiotensin II receptor antagonist used mainly for treatment of hypertension. Results from the CHARM (Candesartan in Heart failure - Assessment of moRtality and Morbidity) study in the early 2000s demonstrated the morbidity and mortality reduction benefits of Candesartan therapy in congestive heart failure. Candesartan cilexetil is sold under the brand name “Atacand” in the United States by ASTRAZENECA. So, the aim of the present study is to develop and evaluate Candesartan cilexetil bilayered tablets.Candesartan cilexitil immediate release formulation were prepared by direct compression technique using Cross povidone as super disintegrant in order to enhance its solubility and bioavailability and S.R formulation were prepared by direct compression technique using carbopol as polymer In total 21(9 I.R and12S.R )formulations have been prepared. Precompression and post compression parameters have been evaluated. The dissolution studies were carried out using USP Type 2 apparatus. Among the formulations F-12 showing a maximum drug release of 99.9% in 16 hrs was selected as the best one.

Keywords: Candesartan cilexitil, bilayered tablets, direct compression technique Cross povidone, carbopol